Syndax Pharmaceuticals logo

Syndax PharmaceuticalsNASDAQ: SNDX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 March 2016

Next earnings report:

05 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.68 B
-21%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector
-37%vs. 3y high
76%vs. sector
478.73
-20%vs. 3y high
97%vs. sector

Price

after hours | 92 min ago
$19.69+$0.19(+0.97%)

Dividend

No data over the past 3 years
$3.50 M$11.20 M
$3.50 M-$68.06 M

Analysts recommendations

Institutional Ownership

SNDX Latest News

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com05 November 2024 Sentiment: -

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago.

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
prnewswire.com04 November 2024 Sentiment: POSITIVE

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Company through profitability; proforma cash approaching $800 million as of June 30 WALTHAM, Mass. and NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (axatilimab-csfr).

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com01 November 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2024 the Company granted inducement awards to purchase up to 78,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan.

Syndax Announces Participation in November Investor Conferences
prnewswire.com01 November 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
prnewswire.com29 October 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 5, 2024.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com04 October 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Oct. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2024 the Company granted inducement awards to purchase up to 62,700 shares of common stock to five new employees under the Company's 2023 Inducement Plan.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com06 September 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Sept. 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on September 1, 2024 the Company granted an inducement award to purchase up to 60,000 shares of common stock to one new employee under the Company's 2023 Inducement Plan.

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript
seekingalpha.com02 August 2024 Sentiment: NEUTRAL

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript

FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
investopedia.com29 July 2024 Sentiment: NEGATIVE

Shares of Syndax Pharmaceuticals (SNDX) plunged in intraday trading Monday after the biopharmaceutical company reported that the Food and Drug Administration (FDA) delayed a decision on approving its experimental treatment for acute leukemia.

Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
prnewswire.com25 July 2024 Sentiment: POSITIVE

WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2024 financial results and provide a business update on Thursday, August 1, 2024.

  • 1(current)

What type of business is Syndax Pharmaceuticals?

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

What sector is Syndax Pharmaceuticals in?

Syndax Pharmaceuticals is in the Healthcare sector

What industry is Syndax Pharmaceuticals in?

Syndax Pharmaceuticals is in the Biotechnology industry

What country is Syndax Pharmaceuticals from?

Syndax Pharmaceuticals is headquartered in United States

When did Syndax Pharmaceuticals go public?

Syndax Pharmaceuticals initial public offering (IPO) was on 02 March 2016

What is Syndax Pharmaceuticals website?

https://www.syndax.com

Is Syndax Pharmaceuticals in the S&P 500?

No, Syndax Pharmaceuticals is not included in the S&P 500 index

Is Syndax Pharmaceuticals in the NASDAQ 100?

No, Syndax Pharmaceuticals is not included in the NASDAQ 100 index

Is Syndax Pharmaceuticals in the Dow Jones?

No, Syndax Pharmaceuticals is not included in the Dow Jones index

When was Syndax Pharmaceuticals the previous earnings report?

No data

When does Syndax Pharmaceuticals earnings report?

The next expected earnings date for Syndax Pharmaceuticals is 05 November 2024